BMO Capital Maintains Stride(LRN.US) With Buy Rating, Raises Target Price to $161
BMO Capital Reaffirms Their Buy Rating on Stride (LRN)
Barrington Maintains Stride(LRN.US) With Buy Rating, Raises Target Price to $170
Stride Analyst Ratings
Barrington Research Adjusts Stride's Price Target to $170 From $150, Keeps Outperform Rating
Morgan Stanley Raises Price Target on Stride to $148 From $141, Keeps Equalweight Rating
William Blair Maintains Stride(LRN.US) With Buy Rating
Stride's Strong Financial Performance and Optimistic Future Guidance Justify Buy Rating
CCORF Maintains Stride(LRN.US) With Buy Rating, Raises Target Price to $155
Stride Price Target Raised to $155.00/Share From $145.00 by Canaccord Genuity
Stride Analyst Ratings
Morgan Stanley Maintains Stride(LRN.US) With Hold Rating, Raises Target Price to $141
Stride's Growth Potential Balanced by Regulatory Risks and Enrollment Uncertainty: Hold Rating Maintained
Barrington Maintains Stride(LRN.US) With Buy Rating, Raises Target Price to $150
Stride Analyst Ratings
Barrington Research Maintains Outperform on Stride, Raises Price Target to $150
BMO Capital Maintains Stride(LRN.US) With Buy Rating, Raises Target Price to $139
Stride Is Maintained at Outperform by BMO Capital
Stride Analyst Ratings
Buy Rating for Stride: Strong Positioning Amid Stock Pullback and Enrollment Growth